Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results
Investigational drug abaloparatide-SC shows continued clinical benefit across the 25-month period with significant reductions in vertebral, nonvertebral, clinical and major osteoporotic fractures. In the first six months of ACTIVExtend, patients who previously completed 18 months of
View HTML
Toggle Summary Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive  Safety similar among all treatment groups with no cases of ONJ or AFF across the entire TYMLOS development program Planned
View HTML
Toggle Summary Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems
Proof of Concept Demonstrated for Abaloparatide Transdermal Short Wear-Time Patch; Phase 2 Results for Abaloparatide Subcutaneous Injection Arm Consistent With Prior Phase 2 Data; Both Studies Continue to Support Potential of Abaloparatide to Be Best-in-Class Bone-Building Therapy
View HTML
Toggle Summary Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
Results show consistency of Abaloparatide-SC responses across a wide range of patient subgroups
View HTML
Toggle Summary Radius Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)
Radius Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)   CAMBRIDGE, MA--(Marketwired - May 5, 2014) - Radius Health Announces Scientific
View HTML
Toggle Summary Radius Announces Three Oral Presentations for Abaloparatide-SC at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease
-Highlights from Phase 3 ACTIVE and ACTIVExtend Trials- -New Results from WHO FRAX ® assessment of ACTIVE Trial demonstrate consistency of fracture risk reduction- -WCO-IOF-ESCEO Malaga 2016 is the largest forum for clinical research and education in osteoporosis, osteoarthritis and musculoskeletal
View HTML
Toggle Summary Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis
Technical Feasibility Demonstrated for Transdermal Delivery of BA058; Study Endpoints of Pharmacokinetic Profile, Safety, and Tolerability Successfully Met; Results Support Plan for Future Phase 2 Proof-of-Concept Clinical Trial
View HTML
Toggle Summary Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing CAMBRIDGE, MA--(Marketwire - Dec 16, 2011) - Radius Health, Inc. ("Radius") announced today the closing of the third and final equity tranche of the company's $91 million financing round announced in May
View HTML
Toggle Summary Radius Closes $27.65 Million Second Tranche of Previously Announced Financing View HTML
Toggle Summary Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis CAMBRIDGE, MA--(Marketwire - Jan 3, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and
View HTML